Harold J. Burstein mainly investigates Internal medicine, Breast cancer, Oncology, Chemotherapy and Cancer. His work in Metastatic breast cancer, Adjuvant therapy, Mastectomy, Neoadjuvant therapy and Survival rate are all subfields of Internal medicine research. His Breast cancer research incorporates themes from Radiation therapy, Randomized controlled trial, Surgery, Guideline and Gynecology.
His Oncology research includes themes of Trastuzumab, MEDLINE, Breast disease, Tamoxifen and Disease. His work on Lapatinib as part of general Trastuzumab study is frequently connected to Vinorelbine, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His biological study spans a wide range of topics, including Regimen, Clinical trial and Mammary gland.
His scientific interests lie mostly in Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. He regularly ties together related areas like Surgery in his Internal medicine studies. His Oncology research also works with subjects such as
His study looks at the relationship between Breast cancer and fields such as Disease, as well as how they intersect with chemical problems. The concepts of his Cancer study are interwoven with issues in Adverse effect, Intensive care medicine, Family medicine and Pathology. The various areas that he examines in his Trastuzumab study include Regimen, Chemotherapy regimen, Paclitaxel and Anthracycline.
His primary scientific interests are in Internal medicine, Oncology, Breast cancer, Adjuvant and MEDLINE. He has researched Oncology in several fields, including Trastuzumab, Early breast cancer, Recurrence score, Palbociclib and Estrogen. His work carried out in the field of Breast cancer brings together such families of science as Stage and Randomized controlled trial.
His Adjuvant study combines topics from a wide range of disciplines, such as Pharmaceutical Adjuvants, Endocrine therapy and Paclitaxel. His research investigates the connection between MEDLINE and topics such as Medical physics that intersect with issues in Sunitinib. His Chemotherapy research integrates issues from Aromatase inhibitor, Tamoxifen, Exemestane and Quality of life.
Harold J. Burstein focuses on Breast cancer, Internal medicine, Oncology, Chemotherapy and Randomized controlled trial. His work on Systemic therapy as part of his general Breast cancer study is frequently connected to Context, thereby bridging the divide between different branches of science. His work on Cancer, Clinical endpoint, Primary therapy and Stage as part of general Internal medicine study is frequently linked to Watchful waiting, bridging the gap between disciplines.
His work in the fields of Oncology, such as Adjuvant, overlaps with other areas such as Annals. His Chemotherapy research includes elements of Aromatase inhibitor, Tamoxifen, Exemestane and Quality of life. Harold J. Burstein has included themes like Survival rate and Clinical trial in his Randomized controlled trial study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A Goldhirsch;E P Winer;A S Coates;R D Gelber.
Annals of Oncology (2013)
Clinical practice guidelines in oncology
William J. Gradishar;Benjamin O. Anderson;Ron Balassanian;Sarah L. Blair.
Journal of The National Comprehensive Cancer Network (2018)
American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
Gary H. Lyman;Armando E. Giuliano;Mark R. Somerfield;Al B. Benson.
Journal of Clinical Oncology (2005)
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004
Eric P. Winer;Clifford Hudis;Harold J. Burstein;Antonio C. Wolff.
Journal of Clinical Oncology (2002)
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
Kimberly L. Blackwell;Harold J. Burstein;Anna Maria Storniolo;Hope Rugo.
Journal of Clinical Oncology (2010)
Ductal Carcinoma in Situ of the Breast
Harold J. Burstein;Kornelia Polyak;Julia S. Wong;Susan C. Lester.
The New England Journal of Medicine (2004)
American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
Harold J. Burstein;Ann Alexis Prestrud;Jerome Seidenfeld;Holly Anderson.
Journal of Clinical Oncology (2010)
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
Johanna C. Bendell;Susan M. Domchek;Harold J. Burstein M.D.;Lyndsay Harris.
Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Gary H. Lyman;Sarah Temin;Stephen B. Edge;Lisa A. Newman.
Journal of Clinical Oncology (2014)
Use of alternative medicine by women with early-stage breast cancer.
Harold J. Burstein;Shari Gelber;Edward Guadagnoli;Jane C. Weeks.
The New England Journal of Medicine (1999)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: